Real-Time Margin Measurement
for Precision Cancer Surgery
Navigation Sciences is developing the NaviSci™ system to address the growing need to locate and remove lung and other soft tissue cancers.
- Reduce early-stage cancer recurrence risk
- Conserve lung function
- Improve surgical workflow
- Shorten hospital length of stay
NaviSci’s first application is in early-stage lung cancer, where there are more than 76,000 new cases each year in the U.S.; the number is growing annually due to increasing adoption of CT x-ray screening.
Overall, there are approximately 450,000 soft tissue cancer diagnoses annually in the U.S. where NaviSci has potential application.
Navigation updates in Q1 2022 newsletter Read more
Navigation Sciences presents at 2022 LSI Emerging Medtech Summit Read more
NaviSci Q/4 2021 Year in Review | Progress updates in the development of our NaviSci™ Intelligent Surgical System for the localization and removal of early-stage lung tumors Read more
NaviSci Q3/ 2021 Progress updates in the development of our NaviSci™ Intelligent Surgical System for the localization and removal of early-stage lung tumors Read more
Navigation Sciences™ Awarded $400,000 NCI SBIR/STTR Program Grant to Support Development of NaviSci™ Intelligent Surgical System Use in Removal of Early-Stage Lung Tumors Read more
Joining Navigation Sciences board of directors are Carl Berke, Ph.D. Partner at the MassGeneral Brigham Venture, and Steve Gullans, Ph.D. Principal at Gullans Advisory Read more
NaviSci is based on technology developed by the company’s co-founders, leaders in thoracic surgery and advanced surgical navigation technology, Raphael Bueno, M.D., Chief, Thoracic Surgery, and Jayender Jagadeesan, Ph.D., Associate Professor of Radiology both at Brigham & Women’s Hospital and Harvard Medical School. View our leadership team